Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance — Stella

Recruiting

Back to Monoclonal Gammopathy trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

Trial locations(2 sites)

United States

Massachusetts General Hospital, Renal Associates Clinic, Boston, Massachusetts

Columbia University Irving Medical Center, New York, New York

Key details

Phase

Safety & dosing

Sponsor

Columbia University

Collaborators

Genzyme, a Sanofi Company

Enrollment target

~27 participants

Started

June 2021

Primary completion

April 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated June 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov